Cold sore virus engineered to attack breast cancer shows promise in early trial
NCT ID NCT02779855
First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 21 times
Summary
This study tested whether injecting a modified herpes virus (talimogene laherparepvec) directly into breast tumors, alongside standard chemotherapy before surgery, could destroy more cancer cells in people with triple negative breast cancer. The virus is designed to infect and break open cancer cells while leaving healthy cells alone, and may also help the immune system fight the tumor. The trial enrolled 50 participants and measured the highest safe dose and the rate of complete tumor disappearance after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.